F
Federico Falchi
Researcher at Istituto Italiano di Tecnologia
Publications - 43
Citations - 1166
Federico Falchi is an academic researcher from Istituto Italiano di Tecnologia. The author has contributed to research in topics: Docking (molecular) & Virtual screening. The author has an hindex of 18, co-authored 41 publications receiving 957 citations. Previous affiliations of Federico Falchi include University of Siena & University of Bologna.
Papers
More filters
Journal ArticleDOI
Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validation.
Giovanni Maga,Federico Falchi,Marco Radi,Lorenzo Botta,Gianni Casaluce,Martina Bernardini,Hamid Irannejad,Fabrizio Manetti,Anna Garbelli,Alberta Samuele,Samantha Zanoli,José A. Esté,Emmanuel Gonzalez,Elisa Zucca,Stefania Paolucci,Fausto Baldanti,Jan De Rijck,Zeger Debyser,Maurizio Botta,Maurizio Botta +19 more
TL;DR: A hit optimization protocol applied to the first nonnucleoside inhibitor of the ATPase activity of human DEAD‐box RNA helicase DDX3 led to the design and synthesis of second‐generation rhodanine derivatives with better inhibitory activity toward cellularDDX3 and HIV‐1 replication.
Journal ArticleDOI
Pharmacophore modeling and molecular docking led to the discovery of inhibitors of human immunodeficiency virus-1 replication targeting the human cellular aspartic acid-glutamic acid-alanine-aspartic acid box polypeptide 3.
Giovanni Maga,Federico Falchi,Anna Garbelli,Amalia Belfiore,Myriam Witvrouw,Fabrizio Manetti,Maurizio Botta +6 more
TL;DR: This compound, identified by means of a computational protocol based on pharmacophoric modeling and molecular docking calculations, represents the first small molecule with such a mechanism of action and could lay the foundations for a pioneering approach for the treatment of HIV-1 infections.
Journal ArticleDOI
Discovery of the first small molecule inhibitor of human DDX3 specifically designed to target the RNA binding site: Towards the next generation HIV-1 inhibitors
Marco Radi,Federico Falchi,Anna Garbelli,Alberta Samuele,Vincenzo Bernardo,Stefania Paolucci,Fausto Baldanti,Silvia Schenone,Fabrizio Manetti,Giovanni Maga,Maurizio Botta,Maurizio Botta +11 more
TL;DR: The identification of the first small molecules specifically designed to inhibit the HIV-1 replication by targeting the RNA binding site of the human DEAD-Box RNA helicase DDX3 is described.
Journal ArticleDOI
Fyn kinase in brain diseases and cancer: the search for inhibitors.
Silvia Schenone,Chiara Brullo,Francesca Musumeci,Mariangela Biava,Federico Falchi,Maurizio Botta +5 more
TL;DR: This review reports some examples of small molecule tyrosine kinase inhibitors for which data on Fyn inhibition, both in enzymatic and in cell assays, have been reported, with the aim of giving information as starting point for the researchers working in this field.
Journal ArticleDOI
Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication.
Anna Garbelli,Marco Radi,Federico Falchi,Sandra Beermann,Samantha Zanoli,Fabrizio Manetti,Ursula Dietrich,Maurizio Botta,Giovanni Maga +8 more
TL;DR: The identification of compounds suppressing HIV-1 replication by targeting the cellular DEAD-box helicase DDX3 provides a proof-of-principle for the feasibility of blocking HIV- 1 infection by rendering the host cell environment less favorable for the virus.